China Banned the use of Cannabis-derived Ingredients in Cosmetic Products
Cannabis-derived ingredients, especially CBD, are popular compounds in the beauty industry. Despite being one of the world’s largest producers of hemp, China has mandated a ban on some cannabis-derived ingredients in cosmetic products, while its neighbouring countries are doing the opposite.

CHINA – ONE OF THE WORLD LARGEST PRODUCER OF HEMP

Since 1985, marijuana is classified in China as a dangerous narcotic and the possession of hemp seeds is illegal. Nevertheless, China represents one of the world’s largest producer of hemp (a strain of Cannabis sativa) but most of it has exportation as its final destination. Hemp production is allowed in the provinces of Yunnan, Heilongjiang and Jilin, representing in 2019 about half of the world’s hemp resources (3 regions together), according to the US Foreign Agricultural Service. Chinese hemp is mainly used in cosmetics but also in electronic cigarettes, medicines and animal feed.

PROHIBITION OF CANNABIS-DERIVED INGREDIENTS IN CHINA

On March 26, China’s National Institute for Food and Drug Control (NIFDC) has presented a proposal to ban some cannabis-derived ingredients in cosmetic and personal care products. Cannabis sativa leaf extract Cannabis sativa seed oil, Cannabis sativa fruit and Cannabidiol (CBD) are some of the ingredients proposed to be prohibited. A public consultation was opened and stakeholders could send comments to the NFDC (by email) until April 19 (2021) in order to allow the government to make the appropriate decision.

Last month (May 28th), the National Medical Products Administration (NMPA) released and implemented the finalized Inventory of Prohibited Ingredients for Cosmetics and Inventory of Prohibited Plant (Animal) Ingredients for Cosmetics. 24 new prohibited cosmetic ingredients were added to these inventories. Among them were Cannabidiol and 3 other Cannabis Sativa-derived ingredients, which are now prohibited from being produced and imported in China.

This new legislation is controversial, especially because an ordinance, published in 2015, allowed the use of these cannabis-derived ingredients (CBD from hemp and products containing less than 0.3% THC) in cosmetic products available in the Chinese market.

In one of our previous posts, we have already discussed the increasing importance of cannabis-derived ingredients in cosmetic and personal care products. In the last few years these compounds have been increasingly used in cosmetics, not only in China, but also around the globe. These ingredients have shown beneficial effects on the skin, like hydration and helping on inflammation reduction. The use of skincare and beauty products containing CBD has become a major beauty trend.

The ban of these ingredients will have repercussions at national level, but also at international level. These compounds are highly sought after and allowed in other markets like the European Union (EU). Exports and e-commerce will be strongly affected.

Other countries are approving the use of cannabis ingredients in cosmetics. Thailand is one of those countries. January this year, Thailand officially legalized the use of 9 low-THC cannabis and hemp ingredients in cosmetics. Usage restrictions and labelling requirements were laid down in two business guidelines in order to regulate the use of these ingredients. For example, cosmetics produced domestically may contain the cannabis-based allowed ingredients but cosmetics containing these ingredients can not be imported.

In sum, although China government allows the cultivation of hemp, it criminalizes its possession. The ban of cannabis-derived ingredients in cosmetics will have strong consequences on the beauty market, making exportation and selling online cosmetics containing these compounds prohibited.

References:

  1. Breaking News! China to Ban CBD and 3 Other Cannabis sativa Derived Ingredients in Cosmetics. Chemlinked. Available from: https://cosmetic.chemlinked.com/news/cosmetic-news/breaking-china-to-ban-cbd-and-other-3-cannabis-sativa-derived-ingredients-in-cosmetics
  2. CBD will be Banned in China. CosmeticsBridge Asia-Pacific. Available from: https://www.cosmeticsbridge.com/cbd-will-be-banned-in-china/

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »